bluebird bio, Inc. (BLUE) Financial Statements (2026 and earlier)

Company Profile

Business Address 455 GRAND UNION BOULEVARD
SOMERVILLE, MA 02145
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments62,30570,651144,067212,047221,755174,293
Cash and cash equivalent62,30570,651144,067212,047221,755165,347
Short-term investments      8,946
Restricted cash and investments334,3601,1543,8669,202 
Receivables      23,000
Inventory, net of allowances, customer advances and progress billings65,01753,94433,33030,30522,91920,969
Inventory65,01753,94433,33030,30522,91920,969
Prepaid expense10,6347,55310,53911,51114,80011,431
Other current assets      17,383
Other undisclosed current assets16,67914,30314,42613,87213,009 
Total current assets:154,668150,811203,516271,601281,685247,076
Noncurrent Assets
Operating lease, right-of-use asset176,883183,098189,206195,209201,113294,717
Property, plant and equipment 62,59378,75690,366 9,972
Intangible assets, net (including goodwill), including:31,50015,42615,65815,89016,08411,014
Goodwill5,6465,6465,6465,6465,6465,646
Intangible assets, net (excluding goodwill)9,5479,78010,01210,24410,4385,368
Other undisclosed intangible assets, net (including goodwill) 16,307     
Restricted cash and investments 43,605   43,640 
Other noncurrent assets52,64053,12858,05758,41754,34350,829
Other undisclosed noncurrent assets 936   22,296 
Total noncurrent assets:305,564314,245341,677359,882337,476366,532
TOTAL ASSETS:460,232465,056545,193631,483619,161613,608
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities53,81543,66455,84539,26547,50650,039
Accounts payable34,31624,48130,59119,38718,49819,852
Accrued liabilities19,49919,18325,25419,87829,00830,187
Deferred revenue      9,653
Debt160,384166,781171,178183,20784,705 
Customer refund liability     5,600 
Other undisclosed current liabilities107,26385,58770,90771,10162,30299,265
Total current liabilities:321,462296,032297,930293,573200,113158,957
Noncurrent Liabilities
Long-term debt and lease obligation7,7965,67519,65526,08937,732 
Finance lease, liability7,7965,67519,65526,08937,732 
Liabilities, other than long-term debt162,508169,135174,627180,775186,779232,115
Other liabilities9471,07992929292
Operating lease, liability161,561168,056174,535180,683186,687232,023
Total noncurrent liabilities:170,304174,810194,282206,864224,511232,115
Total liabilities:491,766470,842492,212500,437424,624391,072
Equity
Equity, attributable to parent(31,534)(5,786)52,981131,046194,537222,536
Common stock1,9231,9171,9161,9131,9051,071
Additional paid in capital4,469,7194,466,1414,464,7124,461,3734,454,7564,333,594
Accumulated other comprehensive loss(2,133)(1,511)(2,122)(2,108)(1,796)(2,227)
Accumulated deficit(4,501,043)(4,472,333)(4,411,525)(4,330,132)(4,260,328)(4,109,902)
Total equity:(31,534)(5,786)52,981131,046194,537222,536
TOTAL LIABILITIES AND EQUITY:460,232465,056545,193631,483619,161613,608

Income Statement (P&L) ($ in thousands)

3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
Revenues38,52110,61216,10118,5737,83412,392
Sublease income9,43510,21910,26010,346  
Cost of revenue(22,789)(11,781)(28,946)(25,864)(9,632)(10,955)
Gross profit:15,732(1,169)(12,845)(7,291)(1,798)1,437
Operating expenses(52,190)(65,750)(75,547)(71,401)(80,875)(86,166)
Operating loss:(36,458)(66,919)(88,392)(78,692)(82,673)(84,729)
Nonoperating income13,55711,83112,47313,74418,42410,544
Investment income, nonoperating1,1621,6402,8372,579  
Other nonoperating income12,39510,1919,63611,165 10,544
Interest and debt expense(5,704)(5,778)(5,453)(4,856)  
Other undisclosed loss from continuing operations before equity method investments, income taxes     (16,353) 
Loss from continuing operations before equity method investments, income taxes:(28,605)(60,866)(81,372)(69,804)(80,602)(74,185)
Other undisclosed income (loss) from continuing operations before income taxes     (7,958)2,454
Loss from continuing operations before income taxes:(28,605)(60,866)(81,372)(69,804)(88,560)(71,731)
Income tax expense (benefit)(107)58(21) 46 
Net loss available to common stockholders, diluted:(28,712)(60,808)(81,393)(69,804)(88,514)(71,731)

Comprehensive Income ($ in thousands)

3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
Net loss:(28,712)(60,808)(81,393)(69,804)(88,514)(71,731)
Other undisclosed comprehensive income     2,274 
Comprehensive loss:(28,712)(60,808)(81,393)(69,804)(86,240)(71,731)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(622)611(14)(312)(1,843)137
Comprehensive loss, net of tax, attributable to parent:(29,334)(60,197)(81,407)(70,116)(88,083)(71,594)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: